Michelle Bell

San Diego biotech elevates key execs as it advances its inflammation pipeline, backed by Sanofi and Lilly, into a competitive and high-stakes market.

The San Francisco Giants' new deal with Athletic Brewing brings NA beer to Oracle Park, signaling a major shift in sports and mindful drinking.

Silvercrest Asset Management will report its 2025 results on March 17, with investors watching if record AUM growth can overcome rising costs and margin pressure.

The firm continues its monthly dividend while positioning its funds to capitalize on global instability, doubling down on defense, gold, and energy sectors.

Soaring demand for a newly found Dr. Seuss manuscript prompts Random House to double its initial print run, signaling a major publishing event.

A groundbreaking clinical trial shows a nutrition-based therapy extended life by 34% in stage IV pancreatic cancer patients, offering rare hope.

A novel compound, IRX4204, shows promise in preventing triple-negative breast cancer in lab studies, offering new hope for a safe, effective preventative.

I-Pulse's new subsidiary iTerra combines AI and pulsed power to zap weeds at the root, aiming to end agriculture's reliance on chemical herbicides.

As companies embrace connected security, experts warn that neglected systems create major vulnerabilities. Are your facilities leaving you exposed to costly breaches?

Embodied AI firm XGSynBot unveils its Z1 wheeled robot, designed for factory floors, not labs, aiming to solve manufacturing's 'automation paradox'.

Praesidian Capital unites iconic model train maker Lionel with hobby giant Round 2, creating a new collectibles empire focused on innovation and growth.

The historic Harlem bank accuses Dream Chasers Capital Group of failing to comply with rules, escalating a battle over the institution's future and finances.

As firms race to adopt AI, Gartner names BigID a Challenger for its unified platform that tackles the critical challenges of data and AI governance.

New disposable encounter-sensing wristbands unveiled at HIMSS 2026 aim to automate clinical documentation, giving valuable time back to patient care.

After a major clinical trial failure, COSCIENS is shutting down its German pharma unit to focus on its profitable plant-based active ingredients business.

aTyr Pharma heads to a crucial FDA meeting for its lung drug efzofitimod, which missed its main goal but showed significant patient quality-of-life gains.

Sword Health expands its Bloom platform, using AI to offer continuous support for women from fertility to menopause and challenge the fragmented healthcare system.

After a four-year regulatory journey, AquaBoreal's massive salmon farm gets key approval, promising to boost Quebec's food security and revitalize a region.

The U.S. services sector boomed in February, hitting its highest growth in years, but a split economy reveals both soaring industries and struggling sectors.

Beyond just a check, Momentum AMP is embedding its team and training into IndieTech 2027, a strategic move that could reshape agent tech collaboration.